Etrolizumab
Etrolizumab is a monoclonal antibody designed for the treatment of Ulcerative colitis and Crohn's disease. It is developed by Genentech, a member of the Roche Group.
Mechanism of Action[edit]
Etrolizumab is a humanized monoclonal antibody that selectively binds to the beta7 subunit of the integrin heterodimer. This binding inhibits the interaction of the beta7 subunit with MAdCAM-1 and E-cadherin, thereby preventing the migration of leukocytes into gut tissues.
Clinical Trials[edit]
Etrolizumab has been studied in Phase III clinical trials for the treatment of moderate to severe ulcerative colitis and Crohn's disease. The results of these trials are pending.
Side Effects[edit]
The most common side effects of etrolizumab include nausea, headache, fatigue, and abdominal pain. Serious side effects can include infections, infusion reactions, and liver problems.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
